Kanghong Pharmaceutical: Subsidiary injection KH617 clinical trial approved.

On May 26, Kanghong Pharmaceutical announced that its subsidiary, Sichuan Honghe Biotechnology Co., Ltd., has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, approving the clinical trial of this product. The injectable KH617 is the first product from the Honghe Biosynthesis Biological Platform to enter clinical trials and is classified as an innovative Class 1 chemical drug.